Breast Cancer Clinical Trial
CD34 Selection of the Peripheral Blood Stem Cell Graft for Autologous Transplant
Summary
Evaluate the feasibility and safety of autologous transplantation of CD34+Thy-1+ hematopoietic stem cells afer high dose marrow ablative chemotherapy in patients with breast cancer.
Full Description
Selection of CD34+THY-1 Positive Cells From Peripheral Blood Cells Procured for Autologous Hematopoietic Support Following High Dose Treatment with BCNU, Cyclophosphamide & Cisplatin for Stage IV Breast Cancer & Limited Prior Treatment
Eligibility Criteria
Inclusion Criteria:- stage IV breast cancer
primary breast cancer does not express CD34+
adequate organ function
no evidence of active infection Exclusion Criteria:- chemotherapy within 4 weeks
CNS disease
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Stanford California, 94305, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.